SARMs
RAD-150
RAD-150 is a longer-acting analog of RAD-140 studied in lean mass research. Below, we compare vendors currently stocking research-grade RAD-150 — not just a single sales page.
RAD-150 is a longer-acting analog of RAD-140 studied in lean mass research. Below, we compare vendors currently stocking research-grade RAD-150 — not just a single sales page.
Prices and testing claims are pulled from each vendor's product listing. Always confirm current price and COA (Certificate of Analysis) on the vendor's site before buying.
| Vendor | Price | Purity Testing | Code | |
|---|---|---|---|---|
 MuscleChemBest Value |
£44.99 | In-house testing | Buy Here → | |
 UK Sarms |
£54.99 | Third-party COA | Auto-applied | Buy Here → |
 Chemyo |
$79.99 (1g powder) | Third-party COA | Buy Here → | |
 SwissChems |
$89.95 | Third-party COA | Buy Here → | |
 Next Chem |
$89.95 | Third-party COA | Auto-applied | Buy Here → |
RAD-150 is described in the research-chemical marketplace as a long-acting nonsteroidal selective androgen receptor modulator (SARM), related in naming convention to RAD-140 but with a substantially smaller and less independently verified research record.
Research-grade RAD-150 is typically supplied as capsules or a liquid solution, commonly at 10mg per dose, intended for laboratory research use only.
RAD-150 is marketed as sharing RAD-140's androgen-receptor-selective mechanism with a longer duration of action, though this claim is based primarily on vendor and research-community reporting rather than an independently published pharmacokinetic dataset comparable to RAD-140's.
RAD-150 is a newer addition to the SARM research-chemical market, and independently published, peer-reviewed data specific to RAD-150 (as opposed to RAD-140) is very limited at this time.
Where RAD-150 is discussed in research contexts, it is typically compared against the better-established RAD-140 dataset rather than supported by its own dedicated clinical or preclinical trial literature.
Because independently published research on RAD-150 specifically is minimal, its human safety profile is essentially uncharacterized. It has never been evaluated in human clinical trials, is not FDA-approved, and no meaningful independent human safety data exists.
No dosage of any kind has been clinically validated for RAD-150 in humans. Any protocols circulating in research-community sources are anecdotal and not supported by peer-reviewed trial data.
Compound X does not sell RAD-150 directly. We provide independent research, comparisons and vendor links — see the vendor comparison table above for current US, UK, Canada and Australia options.
Independently published data specific to RAD-150 is limited; researchers typically cross-reference the broader SARM structure-activity literature indexed on PubMed under "selective androgen receptor modulator."
New guides, vendor comparisons and compound breakdowns every week.